ClinicalTrials.gg
RecruitingNCT07768865ART-KIDSUpdated Aug 17, 2026

Arterial Stiffness in Children and Young People With Hypertension and Chronic Kidney Disease

An observational study in Chronic Kidney Disease and Hypertension, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by King's College London · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
10 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom — 31 open to participants now, 49 under way, 17 of them phase 3. Renal Insufficiency, Chronic · United Kingdom.

Planned enrollment
27th of 71
200 · median 119
Started
2026
with 8 others
Observational
71 of 229
18 open now
Primary completion
2028-06
later than 37 of 48 live
Registered
227th of 229
by date

Among the 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom, this one is the 27th largest by planned enrollment of the 71 observational ones that give a count, is one of 9 that started in 2026, is one of 71 observational ones, reaches primary completion later than 37 of the 48 other live ones, and was the 227th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

31 of the 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 10 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom, or all of them as a file.
02

Study summary

Age related stiffening and hardening of the arteries is often a slow process, but some conditions such as chronic kidney disease (CKD), seem to increase the rate at which the arteries stiffen even during childhood. High blood pressure (BP) is well known to lead to arterial stiffening and is often seen in children and young people (CYP) with CKD.

A greater risk of arterial stiffening has been reported in children CYP with CKD compared to healthy CYP and this is thought to be related to the development of high BP, heart problems, and the worsening of kidney damage. The cause is unknown and is unlikely due to age related changes in the arterial wall seen in older adults. Potential mechanisms contributing to arterial stiffening in CYP with CKD include i) abnormalities in the interaction between the heart and the aorta (the large artery pumping blood away from the heart to the rest of the body), overactivity of the sympathetic nervous system (SNS), the body's "stress response", or iii) abnormal metabolism seen in CKD, where there are high levels of phosphate and other waste products circulating in the blood as a result of damage to the kidneys.

In this study, the investigators will use a variety of non invasive experimental methods to determine if arterial stiffening seen in CYP with CKD is due solely to increased BP, or whether the other potential factors listed above also contribute. This may help to eventually identify how to prevent or treat arterial stiffness in CYP with CKD and prevent its adverse impact on kidney and heart health in later life. The investigators will compare findings between those with CKD and an age, sex and BP matched control group. This control group will comprise CYP both with high BP (primary hypertension) and without high BP (healthy participants).

Read the detailed description

Methods:

Single time point assessment of aortic stiffness of children and young people with CKD; recruitment target of in total 100 participants, of which: 50 pre-dialysis (CKD stage 1-5), 25 on dialysis (CKD stage 5D) and 25 with kidney transplant (CKD-T) compared to 100 age-, sex- and BP-matched controls. Controls will be sourced from existing funded studies performing similar measurements on young people with primary hypertension and healthy normotensive controls, allowing the investigators to match CKD participants to a control group from across the blood pressure (BP) spectrum.

Longitudinal follow-up for one additional timepoint will be offered to all CKD participants with BP >75th percentile (or >130/80 mmHg in adults). The investigators expect this to be around 25 children and young people over the study time period.

All participants will undergo the following investigations:

  1. 24-hour ambulatory BP.
  2. Blood and urine tests for standard CKD biochemistry, hypertension biomarkers, cardiovascular risk profile and proteinuria.
  3. Arterial applanation tonometry.
  4. Cardiac and aortic MRI.
  5. Echocardiography.
  6. Height, weight and clinical BP.
  7. Tanita body composition.

Assessments will then be repeated in the CKD study group once BP \<75th percentile (or \<130/80 mmHg in adults) is achieved.

In a subset of study participants (n = 25 for each additional intervention), some additional investigations will be performed optionally at the discretion of researchers, patients and families:

  1. Respiratory effort with applanation tonometry before and after effort.
  2. Device guided slow breathing.
  3. Lower limb venous occlusion.

Study visits:

Potential participants will be identified from established CKD clinics and recruited with the help of a study coordinator based at Evelina London Children's Hospital (ELCH). Young adults with CKD will be recruited with the help of the well-established transition and adult CKD clinic at Guy's Hospital, with whom there are long- standing collaborations. Routinely, most children with moderate CKD will be seen at least once every 3-6 months.

Control participants will be included from a contemporaneously funded parallel study and include both children with primary hypertension and healthy normotensive children who have consented for their anonymised research data to be used in other ethically approved studies.

The investigators anticipate study consent and some routine clinic testing to be performed at the time of a planned clinic visit but detailed research related investigations including MRI may require an additional planned study visit lasting 2-4 hours at baseline and again at follow up for each complete set of research investigations. Visits will be conducted at dedicated child and adult Clinical Research Facilities as appropriate.

Participants will visit their usual hospital, have no extra needle pricks for blood tests, have non-invasive research tests offered at flexible timings and be compensated for their time and travel.

As this is an observational study, no study related change in the management of participants will be made.

Following achievement of clinical BP target (\<75th percentile or \<130/80mmHg in adults), assessments similar to baseline will be repeated in all participants and experimental interventions in a subset.

Sample size determination and statistical analysis:

Primary outcome: The mean difference in cfPWV between CYP with pre-dialysis CKD and age/sex/BP matched controls is expected to be \~ 0.8 m/s and with n = 50 in each group and a between-subject SD of 0.7 m/s (in-house from our HOT KID controls), the study will have 80% power (for p \< 0.05) of detecting a difference > 0.4 m/s.

Interventional studies: a sample size n = 25 has similar power to detect a change >0.6 of the within-subject SD for differences in cfPWV, which for a within-subject SD of 0.5 m/s is 0.3 m/s, approximately 50% of the difference between hypertensive and normotensive CYP with CKD.

Longitudinal follow-up: within-subject SD is expected to be slightly greater, but this is offset by the greater sample size, and the investigators expect power to be similar to detect a change of 0.3 m/s, 50% of the difference between CYP with CKD and age-, sex- and BP-matched controls.

Recruitment of dialysis and transplant patients is exploratory at this stage and will generate pilot data, therefore for this study they were not included in the power calculation.

The primary outcome measure will be assessed by students t test and ANOVA, with and without adjustment for confounders including age, sex, ethnicity, renal function, heart rate, use of antihypertensive and BMI.

Effects of interventions and change in outcomes after follow-up will be assessed by repeated measures ANOVA.

Significance is defined as P \< 0.05.

03

Conditions studied

  • Chronic Kidney Disease
  • Hypertension

Keywords

  • Chronic kidney disease
  • Hypertension
  • Arterial stiffness
  • Children
  • Pulse wave velocity
  • Cardiac MRI
04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children and young adults with chronic kidney disease and age-, sex- and gender-matched healthy controls and those with primary hypertension.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For CKD participants:

  • Aged 10-25 years at study entry.
  • Diagnosis of CKD confirmed on at least two assessments 3-months apart; eGFR will be estimated using routine bedside formulae (modified Schwartz). Participants may include those on dialysis or those with a functioning kidney transplant.
  • Able to tolerate study investigations including 24-hour ABPM, echocardiogram, vascular assessments and MRI.

For controls:

  • Aged 10-25 years at study entry
  • Having completed study measurements as part of other research being completed by the research group and having consented to their anonymised data being used in future research within the same research theme.

Exclusion criteria

Exclusion criteria (for all participants):

  • Heart abnormalities or pre-existing cardiac disease including congenital heart disease, previous cardiac surgery or heart failure.
  • Cardiac dysrhythmia.
  • Inability to tolerate the required study investigations (out of office BP monitoring, applanation tonometry, cardiac MRI).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Chronic kidney disease

    Children and young adults with chronic kidney disease: * 50 pre-dialysis (CKD stage 1-5) * 25 on dialysis (CKD stage 5D) * 25 with kidney transplant (CKD-T).

  • Controls

    sex and BP matched control participants comprising both young people with primary hypertension and healthy normotensive

06

What researchers measure

Primary outcomes

  1. Difference in carotid femoral pulse wave velocity

    The difference in carotid femoral pulse wave velocity (m/s) between children and young adults with CKD and age, sex and blood pressure (BP) matched controls.

    Time frame: Baseline (single time point)

Secondary outcomes

  1. Difference in carotid femoral pulse wave velocity once blood pressure is normalised

    The difference in carotid femoral pulse wave velocity (m/s) pre and post anti-hypertensive therapy in children and young adults with CKD.

    Time frame: Baseline; Post anti-hypertensive therapy when a clinical blood pressure target of <75th percentile or <130/80mmHg in adults is achieved (anticipated to be 6-9 months post baseline).

  2. Difference in sympathetic nerve activity

    The difference in markers of sympathetic nerve activity between children and young people with CKD compared to age, sex and BP matched controls as follows: * Plasma catecholamines. * Pulse wave velocity (m/s) difference pre and post device guided slow breathing (DGB). * Pulse wave velocity (m/s) difference pre and post lower limb venous occlusion (LVO)

    Time frame: Baseline (single time point)

  3. Difference in aortic pulse wave velocity

    The difference in aortic pulse wave velocity (m/s) as measured by MRI between children and young adults with CKD and age, sex and BP matched controls.

    Time frame: Baseline (single time point)

  4. Difference in cardiac output - echocardiography

    The difference in cardiac output between CYP with CKD and age, sex and BP matched controls as measured by: Echocardiography

    Time frame: Baseline (single time point)

  5. Difference in cardiac output - Cardiac MRI

    The difference in cardiac output between CYP with CKD and age, sex and BP matched controls as measured by: Cardiac MRI

    Time frame: Baseline (single time point)

07

Study locations

1 of 1 sites recruiting
  • Evelina London Children's Hospital and Guys and St Thomas' NHS Foundation Trust
    London, Greater London SE1 7EH, United Kingdom
    Recruiting
08

References and documents

Publications

  • Gaddum NR, Keehn L, Guilcher A, Gomez A, Brett S, Beerbaum P, Schaeffter T, Chowienczyk P. Altered dependence of aortic pulse wave velocity on transmural pressure in hypertension revealing structural change in the aortic wall. Hypertension. 2015 Feb;65(2):362-9. doi: 10.1161/HYPERTENSIONAHA.114.04370. Epub 2014 Nov 17. PubMed 25403607 ↗
  • Gu H, Azukaitis K, Doyon A, Erdem S, Ranchin B, Harambat J, Lugani F, Boguslavskyi A, Cansick J, Finlay E, Gilbert R, Kerecuk L, Lunn A, Maxwell H, Morgan H, Shenoy M, Shroff R, Subramaniam P, Tizard J, Tse Y, Simpson J, Chowienczyk P, Schaefer F, Sinha MD; HOT-KID study, 4C Study Consortium. Decline in Left Ventricular Early Systolic Function with Worsening Kidney Function in Children with Chronic Kidney Disease: Insights from the 4C and HOT-KID Studies. J Am Soc Echocardiogr. 2024 Mar;37(3):356-363.e1. doi: 10.1016/j.echo.2023.11.013. Epub 2023 Nov 21. PubMed 37993063 ↗
  • Sinha MD, Gu H, Douiri A, Cansick J, Finlay E, Gilbert R, Kerecuk L, Lunn A, Maxwell H, Morgan H, Shenoy M, Shroff R, Subramaniam P, Tizard J, Tse Y, Rezavi R, Simpson JM, Chowienczyk PJ; HOT-KID study. Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial. Lancet Child Adolesc Health. 2023 Jan;7(1):26-36. doi: 10.1016/S2352-4642(22)00302-9. Epub 2022 Nov 25. PubMed 36442482 ↗
  • Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003 Dec;14(12):3239-44. doi: 10.1097/01.asn.0000098687.01005.a5. PubMed 14638922 ↗
  • Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011 Apr;57(4):846-51. doi: 10.1161/HYPERTENSIONAHA.110.164780. Epub 2011 Feb 7. PubMed 21300663 ↗
  • Bruno RM, Ghiadoni L, Seravalle G, Dell'oro R, Taddei S, Grassi G. Sympathetic regulation of vascular function in health and disease. Front Physiol. 2012 Jul 24;3:284. doi: 10.3389/fphys.2012.00284. eCollection 2012. PubMed 22934037 ↗
  • Walther FJ, Siassi B, King J, Wu PY. Normal values of aortic root measurements in neonates. Pediatr Cardiol. 1985;6(2):61-3. doi: 10.1007/BF02282739. PubMed 4059069 ↗
  • Mu M, Wang SF, Sheng J, Zhao Y, Li HZ, Hu CL, Tao FB. Birth weight and subsequent blood pressure: a meta-analysis. Arch Cardiovasc Dis. 2012 Feb;105(2):99-113. doi: 10.1016/j.acvd.2011.10.006. Epub 2012 Feb 14. PubMed 22424328 ↗
  • Holwerda SW, Luehrs RE, DuBose L, Collins MT, Wooldridge NA, Stroud AK, Fadel PJ, Abboud FM, Pierce GL. Elevated Muscle Sympathetic Nerve Activity Contributes to Central Artery Stiffness in Young and Middle-Age/Older Adults. Hypertension. 2019 May;73(5):1025-1035. doi: 10.1161/HYPERTENSIONAHA.118.12462. PubMed 30905199 ↗
  • Faconti L, Farukh B, McNally R, Webb A, Chowienczyk P. Arterial Stiffness Can Be Modulated by Pressure-Independent Mechanisms in Hypertension. J Am Heart Assoc. 2019 Aug 6;8(15):e012601. doi: 10.1161/JAHA.119.012601. Epub 2019 Aug 5. PubMed 31379238 ↗
  • Li Y, Haseler E, McNally R, Sinha MD, Chowienczyk PJ. A meta-analysis of the haemodynamics of primary hypertension in children and adults. J Hypertens. 2023 Feb 1;41(2):212-219. doi: 10.1097/HJH.0000000000003326. Epub 2022 Dec 2. PubMed 36583348 ↗
  • Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial Stiffness and Cardiovascular Risk in Hypertension. Circ Res. 2021 Apr 2;128(7):864-886. doi: 10.1161/CIRCRESAHA.121.318061. Epub 2021 Apr 1. PubMed 33793325 ↗
  • Azukaitis K, Kirchner M, Doyon A, Litwin M, Bayazit A, Duzova A, Canpolat N, Jankauskiene A, Shroff R, Melk A, Querfeld U, Schaefer F; 4C Study Investigators. Arterial Stiffness and Chronic Kidney Disease Progression in Children. Clin J Am Soc Nephrol. 2022 Oct;17(10):1467-1476. doi: 10.2215/CJN.02200222. Epub 2022 Aug 25. PubMed 36008353 ↗
  • Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol. 2007 Nov;18(11):2996-3003. doi: 10.1681/ASN.2006121397. Epub 2007 Oct 17. PubMed 17942964 ↗
  • Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Troger J, Mehls O, Schaefer F. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol. 2005 May;16(5):1494-500. doi: 10.1681/ASN.2004110932. Epub 2005 Mar 16. PubMed 15772249 ↗
  • Covic A, Mardare N, Gusbeth-Tatomir P, Brumaru O, Gavrilovici C, Munteanu M, Prisada O, Goldsmith DJ. Increased arterial stiffness in children on haemodialysis. Nephrol Dial Transplant. 2006 Mar;21(3):729-35. doi: 10.1093/ndt/gfi196. Epub 2005 Oct 12. PubMed 16221688 ↗
  • Savant JD, Betoko A, Meyers KE, Mitsnefes M, Flynn JT, Townsend RR, Greenbaum LA, Dart A, Warady B, Furth SL. Vascular Stiffness in Children With Chronic Kidney Disease. Hypertension. 2017 May;69(5):863-869. doi: 10.1161/HYPERTENSIONAHA.116.07653. Epub 2017 Apr 3. PubMed 28373588 ↗
  • Sinha MD, Keehn L, Milne L, Sofocleous P, Chowienczyk PJ. Decreased arterial elasticity in children with nondialysis chronic kidney disease is related to blood pressure and not to glomerular filtration rate. Hypertension. 2015 Oct;66(4):809-15. doi: 10.1161/HYPERTENSIONAHA.115.05516. Epub 2015 Aug 10. PubMed 26259592 ↗
  • Townsend RR, Anderson AH, Chirinos JA, Feldman HI, Grunwald JE, Nessel L, Roy J, Weir MR, Wright JT Jr, Bansal N, Hsu CY; CRIC Study Investigators. Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). Hypertension. 2018 Jun;71(6):1101-1107. doi: 10.1161/HYPERTENSIONAHA.117.10648. Epub 2018 Apr 30. PubMed 29712736 ↗
  • Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999 May 11;99(18):2434-9. doi: 10.1161/01.cir.99.18.2434. PubMed 10318666 ↗
  • Zanoli L, Empana JP, Perier MC, Alivon M, Ketthab H, Castellino P, Laude D, Thomas F, Pannier B, Laurent S, Jouven X, Boutouyrie P. Increased carotid stiffness and remodelling at early stages of chronic kidney disease. J Hypertens. 2019 Jun;37(6):1176-1182. doi: 10.1097/HJH.0000000000002007. PubMed 30624367 ↗
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018. No abstract available. PubMed 38490803 ↗
  • Kula AJ, Somers MJG; American Society of Pediatric Nephrology. Children with CKD Are Not Little Adults with CKD: Pediatric Considerations for the Advancing American Kidney Health Initiative. Clin J Am Soc Nephrol. 2021 Mar 8;16(3):470-472. doi: 10.2215/CJN.11540720. Epub 2020 Oct 15. No abstract available. PubMed 33060159 ↗
  • de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J, Urbina EM, Zachariah JP, Zaidi AN. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019 Mar 26;139(13):e603-e634. doi: 10.1161/CIR.0000000000000618. PubMed 30798614 ↗
  • Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013 Jul 27;382(9889):339-52. doi: 10.1016/S0140-6736(13)60595-4. Epub 2013 May 31. PubMed 23727170 ↗
  • Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol. 2012 Apr;23(4):578-85. doi: 10.1681/ASN.2011111115. Epub 2012 Mar 1. PubMed 22383696 ↗

Individual participant data

Plan to share: No — IPD will not be shared beyond the study team.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 274 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 24 months is below that.

Counting every sponsor, half of 325 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 17, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Jun 16, 2028
CompletionEst.
Jun 16, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07768865
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Jun 16, 2026
Primary completion
Jun 16, 2028 (estimated)
Completion
Jun 16, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Benjamin Boxer, BSc, PhD
Contact
benjamin.boxer@kcl.ac.uk
+44 20 7188 4770
Louise Keehn, MSc
Contact
louise.keehn@kcl.ac.uk
+44 20 7188 4770
Manish Sinha, PhD, MBBS
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion